Matches in SemOpenAlex for { <https://semopenalex.org/work/W2461269372> ?p ?o ?g. }
- W2461269372 abstract "Background Short‐acting insulin analogue use for people with diabetes is still controversial, as reflected in many scientific debates. Objectives To assess the effects of short‐acting insulin analogues versus regular human insulin in adults with type 1 diabetes. Search methods We carried out the electronic searches through Ovid simultaneously searching the following databases: Ovid MEDLINE(R), Ovid MEDLINE(R) In‐Process & Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid OLDMEDLINE(R) (1946 to 14 April 2015), EMBASE (1988 to 2015, week 15), the Cochrane Central Register of Controlled Trials (CENTRAL; March 2015), ClinicalTrials.gov and the European (EU) Clinical Trials register (both March 2015). Selection criteria We included all randomised controlled trials with an intervention duration of at least 24 weeks that compared short‐acting insulin analogues with regular human insulins in the treatment of adults with type 1 diabetes who were not pregnant. Data collection and analysis Two review authors independently extracted data and assessed trials for risk of bias, and resolved differences by consensus. We graded overall study quality using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) instrument. We used random‐effects models for the main analyses and presented the results as odds ratios (OR) with 95% confidence intervals (CI) for dichotomous outcomes. Main results We identified nine trials that fulfilled the inclusion criteria including 2693 participants. The duration of interventions ranged from 24 to 52 weeks with a mean of about 37 weeks. The participants showed some diversity, mainly with regard to diabetes duration and inclusion/exclusion criteria. The majority of the trials were carried out in the 1990s and participants were recruited from Europe, North America, Africa and Asia. None of the trials was carried out in a blinded manner so that the risk of performance bias, especially for subjective outcomes such as hypoglycaemia, was present in all of the trials. Furthermore, several trials showed inconsistencies in the reporting of methods and results. The mean difference (MD) in glycosylated haemoglobin A1c (HbA1c) was ‐0.15% (95% CI ‐0.2% to ‐0.1%; P value < 0.00001; 2608 participants; 9 trials; low quality evidence) in favour of insulin analogues. The comparison of the risk of severe hypoglycaemia between the two treatment groups showed an OR of 0.89 (95% CI 0.71 to 1.12; P value = 0.31; 2459 participants; 7 trials; very low quality evidence). For overall hypoglycaemia, also taking into account mild forms of hypoglycaemia, the data were generally of low quality, but also did not indicate substantial group differences. Regarding nocturnal severe hypoglycaemic episodes, two trials reported statistically significant effects in favour of the insulin analogue, insulin aspart. However, due to inconsistent reporting in publications and trial reports, the validity of the result remains questionable. We also found no clear evidence for a substantial effect of insulin analogues on health‐related quality of life. However, there were few results only based on subgroups of the trial populations. None of the trials reported substantial effects regarding weight gain or any other adverse events. No trial was designed to investigate possible long‐term effects (such as all‐cause mortality, diabetic complications), in particular in people with diabetes related complications. Authors' conclusions Our analysis suggests only a minor benefit of short‐acting insulin analogues on blood glucose control in people with type 1 diabetes. To make conclusions about the effect of short acting insulin analogues on long‐term patient‐relevant outcomes, long‐term efficacy and safety data are needed." @default.
- W2461269372 created "2016-07-22" @default.
- W2461269372 creator A5002078252 @default.
- W2461269372 creator A5003450870 @default.
- W2461269372 creator A5010704137 @default.
- W2461269372 creator A5018701201 @default.
- W2461269372 creator A5023877066 @default.
- W2461269372 creator A5029048566 @default.
- W2461269372 creator A5033350628 @default.
- W2461269372 creator A5040944309 @default.
- W2461269372 creator A5060354325 @default.
- W2461269372 date "2016-06-30" @default.
- W2461269372 modified "2023-10-14" @default.
- W2461269372 title "Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus" @default.
- W2461269372 cites W1489550151 @default.
- W2461269372 cites W1491534708 @default.
- W2461269372 cites W1524183869 @default.
- W2461269372 cites W165426592 @default.
- W2461269372 cites W1915612727 @default.
- W2461269372 cites W1968406323 @default.
- W2461269372 cites W1968485238 @default.
- W2461269372 cites W1973914781 @default.
- W2461269372 cites W1974814311 @default.
- W2461269372 cites W1977178346 @default.
- W2461269372 cites W1979854075 @default.
- W2461269372 cites W1980796462 @default.
- W2461269372 cites W1982836509 @default.
- W2461269372 cites W1990715478 @default.
- W2461269372 cites W1993305086 @default.
- W2461269372 cites W1995064923 @default.
- W2461269372 cites W1995427842 @default.
- W2461269372 cites W2000247073 @default.
- W2461269372 cites W2000480781 @default.
- W2461269372 cites W2000575957 @default.
- W2461269372 cites W2003757648 @default.
- W2461269372 cites W2006175454 @default.
- W2461269372 cites W2007204858 @default.
- W2461269372 cites W201019284 @default.
- W2461269372 cites W2014259263 @default.
- W2461269372 cites W2021455470 @default.
- W2461269372 cites W2030768028 @default.
- W2461269372 cites W2031801933 @default.
- W2461269372 cites W2035123305 @default.
- W2461269372 cites W2037136528 @default.
- W2461269372 cites W2038198672 @default.
- W2461269372 cites W2040851437 @default.
- W2461269372 cites W2041720523 @default.
- W2461269372 cites W2041878038 @default.
- W2461269372 cites W2046391772 @default.
- W2461269372 cites W2060660918 @default.
- W2461269372 cites W2062772470 @default.
- W2461269372 cites W2063759865 @default.
- W2461269372 cites W2064936958 @default.
- W2461269372 cites W2067884079 @default.
- W2461269372 cites W2070806091 @default.
- W2461269372 cites W2072452722 @default.
- W2461269372 cites W2073049443 @default.
- W2461269372 cites W2073391516 @default.
- W2461269372 cites W2073453161 @default.
- W2461269372 cites W2073977794 @default.
- W2461269372 cites W2078687483 @default.
- W2461269372 cites W2079629654 @default.
- W2461269372 cites W2081528927 @default.
- W2461269372 cites W2086098558 @default.
- W2461269372 cites W2090850267 @default.
- W2461269372 cites W2091225717 @default.
- W2461269372 cites W2091336973 @default.
- W2461269372 cites W2092584240 @default.
- W2461269372 cites W2092653445 @default.
- W2461269372 cites W2096440172 @default.
- W2461269372 cites W2096702065 @default.
- W2461269372 cites W2097076707 @default.
- W2461269372 cites W2098744538 @default.
- W2461269372 cites W2098923148 @default.
- W2461269372 cites W2103940805 @default.
- W2461269372 cites W2104888919 @default.
- W2461269372 cites W2106527155 @default.
- W2461269372 cites W2107372727 @default.
- W2461269372 cites W2108116635 @default.
- W2461269372 cites W2112420821 @default.
- W2461269372 cites W2113086214 @default.
- W2461269372 cites W2119605658 @default.
- W2461269372 cites W2125435699 @default.
- W2461269372 cites W2126196596 @default.
- W2461269372 cites W2126815788 @default.
- W2461269372 cites W2126930838 @default.
- W2461269372 cites W2129121181 @default.
- W2461269372 cites W2130235475 @default.
- W2461269372 cites W2130852467 @default.
- W2461269372 cites W2132584445 @default.
- W2461269372 cites W2134293572 @default.
- W2461269372 cites W2142354180 @default.
- W2461269372 cites W2145548102 @default.
- W2461269372 cites W2150944287 @default.
- W2461269372 cites W2150944713 @default.
- W2461269372 cites W2151797569 @default.
- W2461269372 cites W2152709499 @default.
- W2461269372 cites W2154762745 @default.
- W2461269372 cites W2155727751 @default.
- W2461269372 cites W2155997251 @default.